Brought to you by 
Celgene pays AZ $450mm up front for rights to MedImmune's MEDI4736
06 Oct 2021
Executive Summary
Celgene Corp. licensed global rights to AstraZeneca PLC and MedImmune LLC's MEDI4736 (durvalumab), which it will develop and sell for blood cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene pays AZ $450mm up front for rights to MedImmune's MEDI4736
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice